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Systemic  lupus  erythematosus  is  an  autoimmune  disease  that  manifests  in widespread  complement
activation  and  deposition  of complement  fragments  in  the  kidney.  The  complement  pathway  is  believed
to  play  a  signiﬁcant  role  in the  pathogenesis  and  in the  development  of lupus  nephritis.  Complement
factor  B is  an  important  activator  of the  alternative  complement  pathway  and  increasing  evidence  sup-
ports  reducing  factor  B as a potential  novel  therapy  to lupus  nephritis.  Here  we  investigated  whether
pharmacological  reduction  of  factor  B expression  using  antisense  oligonucleotides  could  be  an  effective
approach  for  the  treatment  of  lupus  nephritis.  We  identiﬁed  potent  and  well  tolerated  factor  B antisense
oligonucleotides  that  resulted  in  signiﬁcant  reductions  in  hepatic  and  plasma  factor  B  levels  when  admin-
istered  to normal  mice.  To  test  the  effects  of factor  B  antisense  oligonucleotides  on  lupus  nephritis,  weupus nephritis
herapeutics
used  two  different  mouse  models,  NZB/W  F1  and  MRL/lpr  mice,  that  exhibit  lupus  nephritis  like  renal
pathology.  Antisense  oligonucleotides  mediated  reductions  in  circulating  factor  B  levels  were  associated
with signiﬁcant  improvements  in renal  pathology,  reduced  glomerular  C3 deposition  and  proteinuria,
and  improved  survival.  These  data  support  the  strategy  of  using  factor  B antisense  oligonucleotides  for
treatment  of  lupus  nephritis  in  humans.
© 2015  The  Authors.  Published  by  Elsevier  GmbH.  This  is an  open  access  article  under  the CC. Introduction
Systemic lupus erythematosus (SLE) is an incurable autoim-
une disease that affects more than one million individuals each
ear (Carroll, 2004). SLE is a multisystem autoimmune disease in
hich the autoantibody response targets a variety of autoanti-
ens of diverse subcellular location. The pathogenesis of SLE is
ue to immune complex deposition, complement activation and
he recruitment of neutrophils (Walport, 2002). Lupus nephritis
LN), the renal manifestations of SLE, may  be the ﬁrst symptomatic
Abbreviations: ApoB, apolipoprotein; ASO, antisense oligonucleotide; C3, com-
lement component 3; FB, complement factor B; SLE, systemic lupus erythematosus;
3G, glomerulopathy; GN, glomerulonephritis; LN, lupus nephritis; mAb, mono-
lonal antibody; MPK, milligram per kilogram.
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.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ﬁnding. The presence of autoantibodies that can form immune
complexes results in the deposition of these complexes in the kid-
neys, contributing greatly to the pathogenesis of LN (Lachmann,
1961; Sterner et al., 2014). Genetic deﬁciency of C1q and C4, the
early components of the classical complement pathway, predispose
individuals to SLE. This is believed to be due to the role that C1q has
in the correct disposal of apoptotic cells and the proper catabolism
of immune complexes. The complement system is under delicate
regulation and even small disruptions in the delicate balance of
activation and regulation can lead to an overreaction of comple-
ment, that triggers inﬂammation and cell lysis. Modulation of the
complement system has been recognized as a promising strategy in
drug discovery, and a number of therapeutic modalities have been
developed (Ricklin and Lambris, 2007). On one hand, the comple-
ment system appears to have protective features as evidenced by
the observation that hereditary homozygous deﬁciencies of classic
pathway components are associated with an increased risk for SLE.
On the other hand, immune complex-mediated activation of com-
plement in affected tissues is clearly evident in both experimental
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Fig. 1. FB-ASOs effectively reduce hepatic FB mRNA and plasma FB of normal mice (A) dose dependent reduction in hepatic FB mRNA after subcutaneous administration of
FB-ASOs. Six to eight weeks old C57BL6 mice were treated for 6 weeks with the indicated weekly doses of FB-ASO via subcutaneous injection. Hepatic FB mRNA levels were
quantiﬁed by qRT-PCR (TaqMan). (B) Dose dependent reduction in plasma FB protein levels after subcutaneous administration of FB-ASOs. FB protein level was  measured by
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he  western blot was done using Image J. FB band intensity was normalized to the le
ukey HSD multiple comparisons
nd human SLE along with pathologic features that are direct con-
equences of complement activation (Bao and Quigg, 2007).
Complement factor B protein (FB) is one of the proteins required
or activation of the alternative pathway. During activation of the
lternative pathway, FB binds to C3b on a pathogen surface and
s cleaved to Ba and Bb by Factor D. Then, properdin binds to
he C3bBb complex and stabilizes it. The C3bBb complex is a C3
onvertase and leads to the formation of more molecules of C3b,
esulting in activation of additional FB and setting up an ampliﬁca-
ion loop for activation of C3 (Muller-Eberhard and Schreiber, 1980;
chreiber et al., 1978). Formation of the C5 convertase C3bBbC3b
ollows with activation of terminal complement components on
he pathogen surface. In SLE, activation of the alternative pathway
an lead to renal tissue damage in disease via the ampliﬁcation loop
n which C3b, activated by immune complex deposition, initiates
he alternative pathway, feeding back on and accentuating C3 acti- at the indicated doses or control ASO was used for the analysis. Quantiﬁcation of
 plasma ApoE. Results represent mean ± SEM. ***P < 0.001; by one way ANOVA with
vation. This activation promotes pro-inﬂammatory mechanisms by
the generation of the chemotactic factor C5a (Sterner et al., 2014).
FB is predominantly produced by hepatocytes and secreted into
blood, (Koskimies et al., 1991; Morgan and Gasque, 1997; Marsh
et al., 2001) although several other cell types can also produce FB
(Ripoche et al., 1988; Strunk et al., 1988; Whaley, 1980). The hep-
atocyte FB is an acute phase reactant; therefore, serum levels of
FB increase during inﬂammation stimulated by cytokines, growth
factors, and bacterial products. High serum levels of complement
factor B split products correlate with increased disease activity in
SLE (Cameron et al., 1973; Perrin et al., 1975).
In this study, we  have investigated whether pharmacological
reduction of FB protein levels using antisense technology could
be an effective approach for the treatment of LN. This antisense
approach utilized an RNase H mechanism to degrade the FB RNA
species. The antisense oligonucleotide (ASO) hybridizes to its com-
plementary RNA target and triggers target cleavage by RNase H1
unobiology 221 (2016) 701–708 703
l
r
h
t
e
p
w
o
c
t
l
r
s
s
2
2
p
s
c
p
a
r
o
n
#
w
F
8
m
A
i
1
t
c
q
2
C
(
L
c
h
W
a
C
w
g
M
l
A
C
#
#
t
o
b
C
t
Fig. 2. Administration of FB-ASO normalizes plasma C3 level in MRL/lpr, NZB/W and
wild type mice. (A) Fourteen weeks old MRL/lpr female mice (n = 10 per group) were
dosed SC for 7 weeks with FB-ASO #2 at 50 mg/kg/wk or control ASO at 50 mg/kg/wk
or  saline. The baseline group included MRL/lpr mice that were sacriﬁced at fourteen
weeks old age and the mice from the different groups were sacriﬁced at the end
of  the study at the age of twenty one weeks old. (B) Sixteen weeks old NZB/W
mice (n = 10 per group) were dosed SC for 7 weeks with FB-ASO #2 or control ASO
at  100 mg/kg/wk, or saline. (C) Eight weeks old wild type C57/BL6 mice (n = 4 per
group) were dosed SC for 7 weeks with FB-ASO #2 or control ASO at 100 mg/kg/wk, or
saline. Plasma C3 level was measured using a clinical analyzer and results represent
mean ± SEM, ***P < 0.05; by one way  ANOVA with Tukey HSD multiple comparisons.T.R. Grossman et al. / Imm
eading to the inhibition of target RNA translation and subsequent
eduction in target protein levels (Bennett and Swayze, 2010). We
ypothesized ASO targeting FB mRNA will reduce FB mRNA levels in
he liver and, as a result, will reduce the circulating FB protein lev-
ls to a sufﬁcient degree that will prevent alternative complement
athway activation. Further, this reduction in alternative path-
ay activity will potentially ameliorate renal disease in models
f LN by lowering the systemic over activation of the alternative
omplement system. Our results show that FB ASO administra-
ion results in a signiﬁcant reduction in liver mRNA and plasma FB
evels, leading to an increase in systemic C3 and improvement in
enal pathology and survival in mouse models of LN. These results
uggest that FB ASO could potentially serve as a novel therapeutic
trategy for LN patients.
. Results
.1. FB ASO administration effectively reduces FB mRNA and FB
rotein levels in cells and in wild type mice
To identify the most efﬁcacious ASOs targeting FB for in vivo
tudies, we designed and screened in vitro over 150 ASOs, speciﬁ-
ally targeting the mouse FB mRNA transcript, for efﬁcacy in mouse
rimary hepatocytes. The two lead ASOs selected for in vivo evalu-
tion, FB-ASO #1 FB-ASO #2, exhibited signiﬁcant dose dependent
eduction of FB mRNA levels in primary hepatocytes (IC50 values
f 0.04 and 0.5 M,  respectively). A control mismatch ASO showed
o change in FB mRNA levels. Administration of FB-ASOs #1 or
2 at 25, 50, 75 and 100 mg/kg/week to wild type mice for six
eeks resulted in a signiﬁcant and dose dependent reduction in
B mRNA levels in the liver. The maximal reduction achieved was
7 ± 7% with ASO #1 and 79 ± 10% with ASO #2. No change in FB
RNA level was observed in livers from mice receiving control
SO (Fig. 1A). Since the liver is the major contributor to circulat-
ng FB protein levels (Koskimies et al. 1991; Morgan and Gasque
997; Marsh et al. 2001), we measured the level of plasma FB pro-
ein and, as expected, dose dependent reductions in hepatic mRNA
orresponded well with the reduction in plasma factor B levels as
uantiﬁed by western blot (Fig. 1B).
.2. FB-ASO administration resulted in normalization of plasma
3 levels in NZB/W F1 and MRL/lpr mice
MRL/MpJ-Faslpr (MRL/lpr) and New Zealand Black/White F1
NZB/W) mouse models were used to investigate the role of FB in
N. Both mouse strains spontaneously develop LN with immune
omplex and complement deposition in glomeruli similar to the
uman disease (Drake et al., 1995; Theoﬁlopoulos and Dixon, 1985;
atson et al., 1992). As MRL/lpr mice age and disease progresses,
lternative pathway activation occurs, resulting in a drop in plasma
3 levels due to the consumption of C3 by the alternative path-
ay. As shown in Fig. 2A, fourteen week old MRL/lpr mice (baseline
roup) have similar plasma C3 levels to WT  mice (30 mg/dL). When
RL/lpr mice were aged for an additional seven weeks, plasma C3
evel dropped to 15 mg/dL (saline group). To test the effects of FB-
SO on alternative pathway activity, we measured the total plasma
3 level in LN mouse models following administration of FB-ASO
2. Our results show that weekly subcutaneous dosing of FB-ASO
2 to MRL/lpr mice for 7 weeks was sufﬁcient to prevent the reduc-
ion in plasma C3 levels in MRL/lpr mice. C3 plasma levels in saline
r control ASO treated mice was reduced to approximately 50% of
aseline level, however, mice receiving FB-ASO maintained normal
3 levels of plasma C3 compared to baseline values (Fig. 2A).
In addition, we tested the effect of FB-ASO on plasma C3 levels in
he NZB/W F1 model (Drake et al., 1995). Administration of FB-ASOA  signiﬁcant increase in plasma C3 level achieved with FB-ASO administration when
compared to saline control in all studies.
#2 to sixteen week old female NZB/W mice for 6 weeks resulted
in an increase in plasma C3 level (Fig. 2B). To test if the elevation
in plasma C3 is unique to mouse models of LN or a general effect
on the alternative pathway, wild type mice were administered with
the same ASO targeting FB (FB-ASO #2) at 100 mg/kg/week or saline
for 6 weeks and measured the effects on plasma C3 levels (Fig. 2C).
Our results show that the effect of increased plasma C3 with reduc-
tion in FB level is not speciﬁc to LN models and is obtained in WT
mice administered with FB-ASO. This suggests that the ASO medi-
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ted reduction in FB leads to a signiﬁcant reduction in alternative
athway activation, demonstrated by prevention of C3 consump-
ion that could potentially slow progression of the disease and lead
o improvement in renal pathology.
.3. FB-ASO administration prevents renal pathology in MRL/lpr
nd NZB/W mice
To test the effects of FB-ASO on LN phenotypes, FB-ASO #1 and
B-ASO #2 were administered to MRL/lpr and NZB/W F1 mice by
nce a week subcutaneous injection and evaluated the effects on
isease progression and renal pathology. At the initiation of the
tudies in these two LN models, the mice did not present with renal
isease and exhibited normal protein to creatinine ratio. The aim
f the studies was  to test if administration of FB-ASO could prevent
isease progression and renal pathology.
MRL/lpr mice spontaneously develop a severe systemic autoim-
une disease similar to human SLE. Glomerular immune deposits
n these mice contain IgG, IgM, IgA, Bf, C3 and C5b-9 (Biesecker et al.,
981; Madaio and Harrington, 2001; Theoﬁlopoulos and Dixon,
985; Watson et al., 1992). To evaluate the effects of FB-ASO on
lomerular immune deposits, we stained, with C3 antibody, kid-
eys from MRL/lpr mice that were administered with control ASO,
aline or FB-ASO #2. A semi-quantitative analysis of the images
easuring the intensity of the C3 stain in the glomeruli was con-
ucted by measuring the C3 staining intensity of ten glomeruli
er kidney from each group. C3 staining of kidney sections from
RL/lpr mice that received FB-ASO #2 for seven weeks, showed
 signiﬁcant improvement in renal C3 accumulation in glomeruli
Fig. 3A) and a signiﬁcant improvement in renal pathology com-
ared to the study controls (Fig. 3B).
In addition, we tested the effects of FB-ASO in NZB/W F1 mice,
hich develop a spontaneous autoimmune disease process with
triking similarities to human SLE. In female NZB/W F1 mice, the
roduction of IgG antinuclear antibodies, including antibodies to
ouble-stranded DNA (dsDNA), is associated with the development
f a severe immune complex-mediated glomerulonephritis that
esults in death from renal failure in virtually all animals by 12
onths of age (Clynes et al., 1998; Drake et al., 1995; Theoﬁlopoulos
nd Dixon, 1985). Seventeen week old female NZB/W mice were
reated with FB-ASO #1 or #2, or control ASO for 20 weeks. Subcu-
aneous dosing of FB-ASO #1 and #2 resulted in a robust reduction
n liver FB mRNA (77% and 85% knockdown, respectively). NZB/W
ice develop severe renal disease and exhibit proteinuria at four
onths of age, which leads to death by the age of six months
Drake et al., 1995). We  evaluated the urinary protein/creatinine
atio at baseline and biweekly starting at week 8 after study initi-
tion and scored the incidence of signiﬁcant proteinuria per group
t the different time points. Signiﬁcant proteinuria was deﬁned
y a MTP/creatinine ratio equal or greater than 10. None of the
ZB/W mice exhibited proteinuria at baseline. The ﬁrst incidence
f signiﬁcant proteinuria was observed 8 weeks after the study
as initiated at age 25 weeks. Our results show that administra-
ion of either FB-ASO #1 or #2 signiﬁcantly reduced proteinuria in
ZB/W mice (Fig. 4A) and improved survival (Fig. 4B). Mice that
ere dosed with FB-ASOs showed 94–100% survival whereas mice
dministered with the control ASO or saline exhibited 60–75% sur-
ival at the end of the study (Fig. 4B). To assess the effect of FB
eduction on C3 deposition in the glomeruli, kidneys from surviving
nimals of the different treatment groups were stained with anti-
3 antibody and the intensity of the C3 stain was measured using a
emi-quantitative analysis. Kidneys from NZB/W mice treated with
B-ASOs had signiﬁcantly lower C3 levels in their glomeruli com-
ared to the saline or control ASO treatment groups (Fig. 4C and
D).logy 221 (2016) 701–708
3. Discussion
SLE is characterized by the presence of immune complexes with
autoantibodies that activate the complement pathway, forming
depositions in the kidneys and contribute greatly to the patho-
genesis of LN, a serious potential complication of SLE (Sterner
et al., 2014). The complement pathway is believed to play a sig-
niﬁcant role in LN pathogenesis (Walport, 2002). Several studies
in LN mouse models support complement inhibition as a potential
therapeutic approach for LN.
Successful animal studies, such as the long-term treatment with
anti-C5 mAb, led to the development of strategies to manipu-
late the complement system in different human diseases (Bao and
Quigg, 2007; Wang et al., 1996). Since a anti-C5 mAb  interacts with
the complement system distal to classical pathway components,
it should not interfere with beneﬁcial immune complex clearance
activities of the classical pathway. Therefore, it is conceivable that
in lupus nephritis, an anti-C5 mAb, such as eculizumab, could pre-
vent direct complement-mediated injury to intrinsic glomerular
cells and attenuate kidney inﬂammation by reducing renal leuko-
cyte recruitment (Rovin and Parikh, 2014). Another explanation is
that the efﬁciency of anti-C5 therapy in SLE mouse models is prob-
ably due to its effect on an internal feedback mechanism, whereby
activated neutrophils liberate elastases that cleave C5. The C5a
fragment formed then recruits and activates further neutrophils
to make more elastase (Sahu and Lambris, 2000). Nevertheless,
an essential component needed to get this complement-mediated
inﬂammation, is the reaction of iC3b with the complement receptor
CR3 on neutrophils. Therefore, downregulation of the ampliﬁca-
tion loop constitutes an important therapeutic approach against
complement mediated inﬂammation (Lachmann, 2009).
Factor B is one of the proteins required for activation of the
alternative pathway and the ampliﬁcation loop and plays an impor-
tant role in C3 activation and consumption in models of immune
complex-associated renal disease. In addition, SLE patients exhibit
an elevated plasma level of C3d, Ba, properdin and FB. The level
of these fragments was directly correlated with the clinical man-
ifestations of SLE (Perrin et al., 1975). Factor B-deﬁcient MRL/lpr
mice were protected from GN (Watanabe et al., 2000). In addition
to demonstrating a signiﬁcant role for the complement system in
lupus GN, these studies illustrated that the alternative pathway
ampliﬁcation loop is relevant in this immune complex-related dis-
ease. Paradoxically, LN mice with factor B deﬁciency were protected
from renal disease, while those with C3 deﬁciency had worsened
renal disease. One conceivable explanation for these data relates to
the need for C3 (and C4) to clear glomerular immune complexes
(Quigg et al., 1998). Consequently, C3-deﬁcient MRL/lpr animals
had considerably more immune deposits in glomeruli, which could
interact with Fc receptors on inﬂammatory cells, promoting renal
disease (Clynes et al., 1998; Sekine et al., 2001).
We have demonstrated that administration of optimized FB-
ASO leads to a signiﬁcant reduction in plasma FB that attenuates
disease in two  different LN mouse models. The mechanism for
the improvement in disease pathology may  involve effects on
the inﬂammatory cascade through decreased C3 activation. We
demonstrated in both models of LN the normalization of plasma
C3 levels following FB-ASO dosing, which are signiﬁcantly reduced
in these models due to over activation of the alternative pathway.
The effects of factor B reduction on normalization of plasma C3 lev-
els appear to be through decreased C3 activation and consumption.
Hence, the pro-inﬂammatory functions of C3 may be diminished
due to the lack of C3 activation via the ampliﬁcation loop.Deﬁciencies within the complement system lead to inappropri-
ate inﬂammation and impaired host defense, which can increase
the risk of infection. There has only been one recorded case of factor
B deﬁciency, and the individual presented with meningococcemia
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Fig. 3. Administration of FB-ASO #2 improves renal pathology in MRL/lpr mice. Fourteen weeks old MRL/lpr female mice (n = 10 per group) were dosed SC for seven weeks
with  FB-ASO #2 at 100 mg/kg/wk, control ASO at 100 mpk  or saline. (A) C3 IHC and semi quantiﬁcation. C3 staining intensity was  measured for 10 glomeruli per kidney
for  each mouse from the different groups. Data are represented as mean intensity per kidney ± SEM, *P < 0.05; one way ANOVA with Tukey HSD multiple comparisons (B)
Renal  pathology score. All kidneys from the different groups were stained with H&E and 10 glomeruli per kidney from each group were scored for the renal pathology
using  the following index. +++: Present with multi-glomerular crescents tubular casts; ++: absent crescents tubular casts with minimal Bowman capsule ﬁbrotic change with
m : abse
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hoderate to severe segmental mesangial cell expansion and GBM thickening; +/++
BM  thickening; +: absent crescents tubular casts with mild to moderate segmenta
y  one way ANOVA using Bartlett’s test.
ut no history of any autoimmune disorder (Botto et al., 2009;
lade et al., 2013). The targeted terminal complement inhibitor
culizumab, which was approved for treatment of patients with
NH and HUS, is a humanized monoclonal antibody that speciﬁcally
inds to the complement protein C5 with high afﬁnity. Although
culizumab is generally well tolerated, the risk of Neisseria menin-
itidis infection is increased with treatment and all patients must
e vaccinated prior to treatment (Keating et al., 2012).
Antisense technology is a highly effective approach for reducing
arget expression in liver (Crooke, 2008.). Here, we show that sub-
utaneous administration of FB-ASOs resulted in a robust reduction
n liver FB mRNA, with corresponding reductions in plasma FB lev-
ls. Our results conﬁrm the important role of complement FB in
he development of GN in LN mouse models. Using FB-ASOs, we
emonstrated normalization of plasma C3 levels and improved LN
n mice, reduced C3 deposits in the glomeruli, improved kidney
istopathology, reduced proteinuria and improved survival. ASOnt crescents tubular casts with moderate segmental mesangial cell expansion and
ngial cell expansion and GBM thickening. Results represent mean ± SEM. *P < 0.05;
utilizing identical chemical modiﬁcations as used in this study, are
being routinely used in the clinical setting today, and have demon-
strated long term therapeutic utility, (Crooke, 2008; Li et al., 2014)
indicating a potential therapeutic opportunity of FB-ASO for a long
term treatment strategy. We  suggest that ASOs targeting FB have
the potential to become a novel therapeutic approach for LN and
other renal diseases, such aHUS and C3G, in which activation of
the alternative complement pathway plays a signiﬁcant role in the
pathogenesis.
4. Materials and methods
4.1. ASO synthesis and chemistryAntisense oligonucleotides (ASOs) used were 20 nucleotides
in length and chemically modiﬁed with phosphorothioate
in the backbone, ﬁve residues at each terminus, and a cen-
706 T.R. Grossman et al. / Immunobiology 221 (2016) 701–708
Fig. 4. Administration of FB-ASOs improves survival, proteinuria and renal pathology in NZB/W F1. Seventeen weeks old NZB/W F1 female mice (n = 10–16 per group) were
dosed  SC with 100 mg/kg/wk of FB-ASOs #1 and #2 or control ASO or saline for twenty weeks. (A) Proteinuria presented as cumulative incidence of signiﬁcant proteinuria
measured by MTP/creatinine ratio. Signiﬁcant proteinuria was deﬁned at MTP/creatinine ratio equal or greater than 10. Tukey HSD multiple comparisons analysis (B) survival
curves. Results represented as percent survival. Statistical analysis Log-rank (Mantel–Cox) test (C) C3 IHC (D) C3 IHC  semi-quantiﬁcation of kidneys from surviving animals.
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tuantiﬁcation of staining pixel density as well as staining area per glomerulus was 
ach  kidney was measured (n = 6–8) resulting in analysis of 60–80 glomeruli per gro
ith  Tukey HSD multiple comparisons.
ral deoxynucleotide region of ten residues (5-10-5 gapmer).
′-O-Methoxyethyl modiﬁed antisense phosphorothioate oligonu-
leotides (2′-MOE ASOs) were synthesized at Isis Pharmaceuticals,
nc. (Carlsbad, CA) as described previously (Baker et al., 1997).
ligonucleotides were synthesized using an Applied Biosys-
ems 380B automated DNA synthesizer (PerkinElmer Life and
nalytical Sciences–Applied Biosystems) and puriﬁed as pre-
iously described (Bennett and Swayze, 2010). Sequences
ere as follows: ASO #1, 5′-GTCCTTTAGCCAGGGCAGCA-3′;
SO #2, 5′-TCCACCCATGTTGTGCAAGC-3′. ASO #3 5′-
TCCGAGTCAGGCTCTTCCC-3′ ASOs were dissolved in PBS (Ca–Mg-;
nvitrogen) for in vivo experiments
.2. Culture of hepatocytes and treatment with ASO
Mouse primary hepatocytes were prepared using the standard
ollagenase procedure described previously (Quistorff et al., 1990).
lectroporation of ASOs was carried out using the HT-200 BTX
lectroporator with the ElectroSquare Porator (ECM 830) volt-
ge source in 96-well electroporation plates (BTX, 2 mm;  Harvard
pparatus). Cells were harvested 16 h after electroporation. Cells
ere electroporated in the presence of FB-ASOs at the indicated
oncentrations and plated. Sixteen hours after transfection, total
ellular RNA was isolated, and the amount of FB mRNA was  quan-
iﬁed using a quantitative RT-PCR (qRT-PCR) assay (TaqMan).cted using Aperio image scope program. C3 staining intensity of 10 glomeruli from
ata are represented as mean intensity per kidney ± SEM, *P < 0.05; one way ANOVA
4.3. Quantitative real-time PCR
Cultured cells were lysed, and total RNA was extracted with
a QIAGEN RNeasy column. Animal tissues were homogenized in
a guanidine isothiocyanate solution (Invitrogen) supplemented
with 8% 2-mercaptoethanol (Sigma–Aldrich). Total RNA was  pre-
pared according to the RNeasy mini kit instructions (QIAGEN). The
qRT-PCR analyses were done using an ABI Prism 7700 sequence
detector (Applied Biosystems). PCR results were normalized to
total RNA measure by Quant-iT RiboGreen RNA Reagent (Molec-
ular Probes). The sequences of primers and probe used were as
follows: FB: forward: 5′- GGGCAAACAGCAATTTGTGA-3′, reverse:
5′- TGGCTACCCACCTTCCTTGT-3′, probe: 5′-Fam- CTGGATACTGTC-
CCAATCCCGGTATTCC -Tamra-3′; PCR results were normalized to
total RNA measure by Quant-iT RiboGreen RNA Reagent (Molecular
Probes).
4.4. Animal studies
Studies were conducted in WT,  NZB/W and MRL/MpJ-Faslpr mice
(Jackson Laboratories, Bar harbor, ME). Mice were housed four ani-
mals per cage at 22–25◦ with 12 h light:dark cycle and free access
to food and water. ASO drugs were prepared in PBS and were
administered by subcutaneous injection. Dosages are reported as
weekly dose for all the animal studies and mice were dosed subcu-
taneously once per week. Plasma was  collected by cardiac puncture
and frozen at −70 ◦C or less. Urine was collected over night on ice
for total protein and creatinine analysis. Urine was stored at −70 ◦C
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r less until analyzed. Liver and kidneys were collected at sacri-
ce approximately 72 h after dosing was completed. Plasma C3,
rine total protein and creatinine levels was measured using the
U480Clinical Analyzer (Beckman Coulter).
.5. Study approval
All the animal studies were conducted under protocols
pproved by the Institutional Animal Care and Use Committee
IACUC) of Isis Pharmaceuticals
.6. Plasma FB western blot
Blood was collected under anesthesia via cardiac puncture into
ample tubes coated with the anticoagulant EDTA. Blood was
entrifuged at 4000 × g for 15 min  and platelet-poor plasma was
ollected and stored at −80 ◦C prior to western blotting. One
icroliter of plasma samples from all groups were analyzed by
odium dodecyl sulfate polyacrylamide gel electrophoresis fol-
owed by immunoblotting with antibodies to FB. Rabbit anti mouse
B (Sigma) at a dilution of 1:1000. Secondary—Goat Anti-Rabbit IgG
RP conjugate at a dilution of 1:8000. Rabbit anti-mouse ApoE anti-
ody (Abcam) at a dilution of 1:5000. Image quantiﬁcation of the
estern blot was done by Image J program (NIH).
.7. Plasma C3 level
Plasma C3 level was measured using the AU480Clinical Analyzer
Beckman Coulter).
.8. Histological analysis
Kidney samples were ﬁxed in 10% buffered formalin and embed-
ed in parafﬁn wax. Multiple adjacent 4 mm sections were cut
nd mounted on glass slides. After dehydration, the sections were
tained with H&E or PAS. IHC for C3, the kidneys were embedded in
CT and frozen sections were mounted on glass slides and stained
ith Rabbit anti mouse anti-C3 antibodies (Sigma) and Donkey anti
ouse IgG (Jackson Immunoresearch Labs). To assess the C3 stain-
ng intensity in kidneys from the different treatment group we  used
 semi quantitative analysis which was done by measuring the pixel
ntensity of the C3 and IgG stain of 10 glomeruli per kidney.
.9. Statistics
Values presented represent as mean ± SEM. Statistical differ-
nce between groups was determined using one way  ANOVA with
ukey HSD multiple comparisons P < 0.05 was considered to be sig-
iﬁcant.
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Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.imbio.2015.08.
001.
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